- Home
- JAGX
JAGX
Jaguar Health Inc.
as 02-21-2025 4:00pm EST
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 12.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 311.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $21.60 | Next Earning Date: | 03-31-2025 |
| Revenue: | $10,480,000 | Revenue Growth: | -2.25% |
| Revenue Growth (this year): | 18.18% | Revenue Growth (next year): | 40.06% |
Latest Jaguar Health Inc. News
JAGX Breaking Stock News: Dive into JAGX Ticker-Specific Updates for Smart Investing
ACCESS Newswire
4 days ago
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
ACCESS Newswire
5 days ago
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
GlobeNewswire
5 days ago
Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now
ACCESS Newswire
10 days ago
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
ACCESS Newswire
17 days ago
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
ACCESS Newswire
20 days ago
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
ACCESS Newswire
25 days ago
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
ACCESS Newswire
a month ago
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
Compare JAGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAGX Jaguar Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.